2-(1'-aminoethyl)bicyclo(2.2.1)heptane is a complex organic molecule with the following structure:
* **Bicyclo(2.2.1)heptane:** This part refers to a specific type of carbon ring structure with 7 carbons arranged in a 3-dimensional cage-like shape.
* **2-(1'-aminoethyl):** This indicates a side chain attached to the second carbon of the bicycloheptane ring. This side chain consists of an ethyl group (CH3CH2-) with an amino group (-NH2) attached to the first carbon.
**Importance in Research:**
This specific compound itself isn't widely studied or particularly well-known for its own unique properties. However, the structural features of this molecule, including the bicyclic framework and the amino group, are relevant in various research areas:
* **Drug Development:** Bicyclic structures are often found in pharmaceuticals due to their rigid structure, which can provide specific binding interactions with biological targets. The amino group can act as a hydrogen bond donor, further enhancing interactions with receptors or enzymes.
* **Organic Synthesis:** The bicyclo(2.2.1)heptane scaffold can serve as a starting point for synthesizing various complex molecules with diverse biological activities.
* **Chirality:** The molecule potentially exists as enantiomers (mirror images) due to the chiral carbon in the aminoethyl side chain. Studying the enantiomers could reveal different biological effects or interactions with target molecules.
**To understand its specific importance, you need to know the context of the research. For example:**
* Is it being used as a **starting material** for synthesizing new drugs?
* Is it being investigated as a **potential drug candidate** itself?
* Is it being used to explore the **relationship between structure and activity** in a particular biological system?
Without further information about the specific research context, it's difficult to pinpoint the precise importance of this molecule.
2-(1'-aminoethyl)bicyclo(2.2.1)heptane: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 161455 |
| CHEMBL ID | 3302756 |
| SCHEMBL ID | 4211835 |
| MeSH ID | M0106241 |
| Synonym |
|---|
| HMS1787D20 |
| OPREA1_877673 |
| STK312711 |
| 1-(bicyclo[2.2.1]hept-2-yl)ethanamine |
| OPREA1_612008 |
| aebch |
| AKOS000115543 |
| 24520-60-3 |
| BBL016032 |
| 1-bicyclo[ |
| (1-bicyclo[2.2.1]hept-2-ylethyl)amine |
| 1-bicyclo[2.2.1]hept-2-ylethanamine |
| 2-(1'-aminoethyl)bicyclo(2.2.1)heptane |
| bicyclo(2.2.1)heptane-2-methanamine, alpha-methyl- |
| (1-bicyclo[ |
| BP-11174 |
| CHEMBL3302756 |
| AB01323546-02 |
| AKOS016042495 |
| SCHEMBL4211835 |
| 1-bicyclo[2.2.1]hept-2-ylethanamine # |
| LPUCHTNHUHOTRY-UHFFFAOYSA-N |
| 1-(5-bicyclo[2.2.1]heptyl)ethylamine |
| 1-(bicyclo[2.2.1]heptan-2-yl)ethanamine |
| VS-05106 |
| 1-{bicyclo[2.2.1]heptan-2-yl}ethan-1-amine |
| EN300-33929 |
| 1-(2-bicyclo[2.2.1]heptanyl)ethanamine |
| bicyclo[2.2.1]heptane-2-methanamine, alpha-methyl- |
| D94621 |
| NCGC00328205-01 |
| DTXSID50947411 |
| 1-(bicyclo[2.2.1]heptan-2-yl)ethan-1-amine |
| AB92437 |
| CS-0187964 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1611059 | Cytotoxicity against dog MDCK cells assessed as cell death incubated for 48 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23 | Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents. |
| AID1611058 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of virus replication compound incubated with uninfected host cell for 1 hr followed by viral infection for 24 hrs measured after vi | 2019 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23 | Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents. |
| AID1611060 | Selectivity index, ratio of CTD50 for dog MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) pdm09 infected in MDCK cells | 2019 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23 | Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||